title: Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer.
abstract: Vasohibin-1 (VASH1) is a newly discovered angiogenesis inhibitor that is specifically expressed in human vascular endothelial cells in response to vascular endothelial growth factor and fibroblast growth factor-2. This study aimed to evaluate the expression of VASH1 in non-small cell lung cancer (NSCLC) and correlates its expression with the clinicopathological parameters and prognosis of the disease. Immunohistochemical analysis was used to determine the expression of VASH1 in NSCLC tissue and adjacent normal tissue from 84 patients. The relationship between VASH1 expression and clinicopathological indicators was examined with the chi-squared test. Moreover, the survival rate was calculated with the Kaplan-Meier survivor curve. Finally, the correlation between the indicators and patient survival was estimated with Cox analysis. VASH1 was high expressed in 63.1% of NSCLC tissues versus 21.4% of adjacent tissues (P < 0.01). High VASH1 expression in NSCLC tissue was correlated with clinicopathological features including lymph node status (P = 0.024) and TNM stage (P = 0.036). The Kaplan-Meier curve indicated that the patients with high VASH1 expression had significantly shorter survival than those with low VASH1 expression. In the multivariate Cox regression model, high VASH1 expression was identified as an independent prognostic factor for patients with NSCLC. High VASH1 expression is predictive of poor prognosis of NSCLC, implying that VASH1 may be a promising new target for targeted therapies for NSCLC.
authors.affiliation: Department of Oncology, The First Hospital of Lanzhou University (The Branch Hospital of Donggang), Lanzhou, 730000, Gansu Province, China.
authors.forename: Tao
authors.initials: T
authors.lastname: Zhang
authors.forename: Ting-Ting
authors.initials: TT
authors.lastname: Yu
authors.forename: Dong-Ming
authors.initials: DM
authors.lastname: Zhang
authors.forename: Xiao-Ming
authors.initials: XM
authors.lastname: Hou
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Liu
authors.forename: Da
authors.initials: D
authors.lastname: Zhao
authors.forename: Li
authors.initials: L
authors.lastname: Shan
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D018797:Cell Cycle Proteins / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008168:Lung / Q000378:metabolism; D008175:Lung Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; C493181:VASH1 protein, human
references.citation: Am J Respir Crit Care Med. 2013 Jul 15;188(2):157-66
references.pmid: 23855692
references.citation: J Intern Med. 2013 Feb;273(2):114-27
references.pmid: 23216836
references.citation: Hum Pathol. 2013 Aug;44(8):1586-96
references.pmid: 23522064
references.citation: Nat Med. 2013 Nov;19(11):1423-37
references.pmid: 24202395
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: PLoS One. 2013 Sep 16;8(9):e73931
references.pmid: 24066086
references.citation: Keio J Med. 2012;61(2):47-56
references.pmid: 22760023
references.citation: Exp Cell Res. 2013 May 15;319(9):1271-80
references.pmid: 23500414
references.citation: Cancer Biol Ther. 2012 Mar;13(5):247-63
references.pmid: 22481432
references.citation: Med Oncol. 2014 Feb;31(2):816
references.pmid: 24366689
references.citation: Clin Cancer Res. 2012 Aug 1;18(15):4145-53
references.pmid: 22675166
references.citation: Reproduction. 2012 Apr;143(4):491-500
references.pmid: 22367587
references.citation: Cancer. 2011 Sep 1;117(17):3889-99
references.pmid: 21858799
references.citation: Cancer Sci. 2010 Feb;101(2):448-52
references.pmid: 19886910
references.citation: Med Oncol. 2012 Dec;29(4):2727-36
references.pmid: 22101788
references.citation: Mol Cancer Res. 2012 Sep;10(9):1135-46
references.pmid: 22826464
references.citation: Med Oncol. 2012 Dec;29(4):2718-26
references.pmid: 22438034
references.citation: Cancer Sci. 2010 Apr;101(4):1051-8
references.pmid: 20704578
references.citation: Curr Opin Oncol. 2014 Mar;26(2):145-51
references.pmid: 24406751
references.citation: Oncogene. 2013 Mar 28;32(13):1724-34
references.pmid: 22614011
references.citation: J Clin Pathol. 2013 Jul;66(7):613-9
references.pmid: 23543668
references.citation: Eur J Cancer. 2013 Dec;49(18):3914-23
references.pmid: 23992642
references.citation: Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15894-9
references.pmid: 22967508
references.citation: J Biochem. 2013 Jan;153(1):5-11
references.pmid: 23100270
references.citation: Med Oncol. 2012 Dec;29(5):3325-34
references.pmid: 22865127
references.citation: Vascul Pharmacol. 2012 May-Jun;56(5-6):262-6
references.pmid: 22286022
references.citation: Cancer Sci. 2011 Feb;102(2):446-51
references.pmid: 21175993
references.citation: Int J Mol Sci. 2013 Apr 29;14(5):9338-64
references.pmid: 23629668
references.citation: Am J Pathol. 2010 Apr;176(4):1950-8
references.pmid: 20133819